PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB

贝伐珠单抗、埃洛替尼、伊马替尼的 I/II 期试验

• 批准号: 7605583
• 负责人: Jeffrey A Sosman
• 金额: $ 1.42万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605583
• 关键词: Bevacizumab/Erlotinib; Computer Retrieval of Information on Scientific Projects Database; Conventional (Clear Cell) Renal Cell Carcinoma; Dose; Drug Combinations; End Point; Funding; Grant; Imatinib; Institution; Patients; Phase; Progression-Free Survivals; Rate; Renal Cell Carcinoma; Research; Research Personnel; Resources; Source; Toxic effect; United States National Institutes of Health; improved; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The combination of bevacizumab, erlotinib and imatinib will be found to substantially improve the response to treatment over bevacizumab and erlotinib alone. " To define tolerable dose levels of bevacizumab, erlotinib, and imatinib when used in combination. " To evaluate the efficacy of this 3-drug combination in the treatment of patients with advanced clear cell renal carcinoma. The primary endpoint in this trial will be the objective response rate. Secondary endpoints will include progression-free survival and overall survival. " To define the overall tolerability and toxicity of this 3-drug combination in advanced renal cell carcinoma.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 与单独使用贝伐单抗和厄洛替尼相比，贝伐单抗、厄洛替尼和伊马替尼的组合将显着改善治疗反应。 “确定贝伐珠单抗、厄洛替尼和伊马替尼联合使用时的耐受剂量水平。 ” 旨在评估这种 3 种药物组合治疗晚期透明细胞肾癌患者的疗效。该试验的主要终点将是客观缓解率。次要终点将包括无进展生存期和总生存期。 “旨在确定这种 3 种药物组合在晚期肾细胞癌中的总体耐受性和毒性。